Schedule your call

Case Study: Pre-Approval (PAI) FDA Mock Audits in CAR-T and Viral Vector Manufacturing Sites

GMP Bridge Content Team

11.03.2026

Case Study

Case Study Overview

FDA inspection readiness is critical for cell and gene therapy manufacturers, where PAIs test both systems and team behavior. This case study shows how GMP Bridge ran PAI-style mock audits at two CGT sites (CAR-T and viral vectors), aligning teams with FDA expectations, identifying compliance gaps early, and building a clear remediation roadmap before the real inspection.

The Challenge

A global biotech company specializing in cell and gene therapies required independent FDA-style Mock Audits to evaluate the readiness of two advanced therapy manufacturing sites. With no recent FDA inspection experience, uncertainty about expectations, and teams unfamiliar with inspection dynamics, the company sought a trusted partner to provide a realistic PAI simulation and actionable feedback.

Solution Delivered

GMP Bridge designed and executed a comprehensive FDA-style mock inspection program to prepare two advanced therapy manufacturing sites for upcoming regulatory inspections.

Mock Inspection Program Design

Designed a comprehensive FDA-style mock audit program tailored to two manufacturing sites producing CAR-T therapies and viral vectors.

Inspection Strategy & Agenda Preparation

Developed detailed inspection agendas and document request lists aligned with FDA’s system-based inspection approach.

On-Site Mock FDA Inspections

Conducted multi-day on-site audits simulating FDA Pre-Approval Inspections (PAIs) across both manufacturing sites

Comprehensive GMP System Audits

Evaluated critical systems including Quality Systems, aseptic operations, sterility assurance, Environmental Monitoring, supplier qualification, and Quality Oversight.

Leadership Debrief & Inspection Readiness Coaching

Delivered detailed post-audit debriefs with site leadership, focusing on inspection behavior, communication, and leadership engagement.

Gap Analysis & Remediation Roadmap

Issued a prioritized audit report identifying critical gaps and providing clear remediation actions to achieve inspection readiness.

Impact and Results

The mock inspection program delivered immediate improvements in inspection readiness, regulatory awareness, and cross-functional alignment across both manufacturing sites.

Inspection Readiness Through Realistic FDA Simulation

Leadership and operational teams gained firsthand exposure to FDA inspection dynamics, expectations, and questioning techniques.

Early Identification of Compliance Risks

Critical compliance gaps and inspection vulnerabilities were identified well ahead of the scheduled FDA inspections.

Strengthened Quality Oversight and Governance

Quality oversight structures and governance mechanisms were reinforced across both manufacturing sites.

Clear Remediation Roadmap

The organization received a prioritized remediation plan to address inspection findings and reduce regulatory risk before FDA arrival.

Improved Alignment Between Quality and Manufacturing

The engagement strengthened collaboration, communication, and alignment between Quality and Manufacturing functions.

Want to see how we can deliver results like this for your site?

Schedule your Call

Company Details

  • Region: DACH
  • Company: global biotech company specialising in gene therapy
  • Products: Autologous CAR-T therapies and viral vectors

Ready to talk the specifics?
So Are we - Get in Touch

  • (+49) 174 957 5861
  • contact@gmpbridge.com

Last Case Studies